Research programme: metabolic disorder therapeutics - Relburn Metabolomics

Drug Profile

Research programme: metabolic disorder therapeutics - Relburn Metabolomics

Alternative Names: RLBN 1001; RLBN 2020 series; RLBN 3010 series

Latest Information Update: 13 Jun 2014

Price : $50

At a glance

  • Originator Relburn Metabolomics
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gout

Most Recent Events

  • 03 Jun 2014 Preclinical trials in Gout in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top